Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $524,625.00. Following the transaction, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at $5,082,315.18. This represents a 9.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.29, for a total value of $253,625.00.

Bicara Therapeutics Trading Up 2.8%

Shares of Bicara Therapeutics stock opened at $24.28 on Friday. The business has a 50-day moving average price of $26.15 and a two-hundred day moving average price of $21.80. Bicara Therapeutics Inc. has a 1-year low of $10.30 and a 1-year high of $30.99. The company has a market cap of $1.61 billion, a P/E ratio of -7.83 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.82). Equities research analysts forecast that Bicara Therapeutics Inc. will post -3.45 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Several large investors have recently made changes to their positions in the company. Siren L.L.C. increased its position in Bicara Therapeutics by 11.2% in the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after buying an additional 586,001 shares in the last quarter. Vestal Point Capital LP raised its stake in Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after buying an additional 100,000 shares during the period. BlackRock Inc. bought a new position in Bicara Therapeutics in the second quarter worth approximately $114,250,000. Janus Henderson Group PLC boosted its holdings in Bicara Therapeutics by 26.2% in the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after acquiring an additional 692,933 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its stake in Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after acquiring an additional 2,771,868 shares during the period.

Analysts Set New Price Targets

A number of brokerages have weighed in on BCAX. Guggenheim began coverage on Bicara Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $42.00 target price for the company. Mizuho increased their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. The Goldman Sachs Group raised their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.73.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.